Related Experiment Video
Updated: Aug 16, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
[Efficacy of galstena in liver damage induced by antitubercular agents]
1Department of Pharmacology, Mordvinian State University, ul. Bol'shevistskaya 68, Saransk, Mordvinia, 430000 Russia.
Abstract:
It is established that galstena possesses hepatoprotector activity and is capable of reducing pathological changes in animals treated with toxic doses of antituberculous drugs. Galstena prevents from the development of cytolysis, as evidence by inhibition of the activity of aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase. The anti cholestatic effect of galstena is confirmed by suppression of the growth in the levels of total bilirubin, alkaline phosphatase, and gamma-glutarate transpeptidase. Galstena was also found to possess antiinflammatory properties. Moreover, a growth in the activity of glutathione-dependent reductase (related to inhibited growth of the iron level in the blood serum) is evidence of the antioxidant activity. In addition, galstena prevents from an increase in the content of creatinine and urea, which is evidenced of decreasing endogenous intoxication.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Antiprotozoal Agents

